Cognes is developing a scalable screening tool utilizing machine learning technology to identify digital biomarkers of dementia at an early stage, a smartphone-based solution to tackle today’s time-consuming and costly diagnostic process. There is great need for scalable, non-invasive and cost-effective digital solutions to stratify patient recruitments for clinical trials and accelerate disease-modifying drugs to get to the market.